Mechanism of Action

DUPIXENT is a dual inhibitor of I⁠L⁠-⁠4 and I⁠L⁠-⁠1⁠3 signaling

Inflammation is an important component in the pathogenesis of asthma

Multiple cell types that express I⁠L⁠-⁠4⁠R⁠α (e.g., mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation:

Mast cells
Eosinophils
Lymphocytes
Epithelial cells

Blocking I⁠L⁠-⁠4⁠R⁠α with dupilumab inhibits I⁠L⁠-⁠4 and I⁠L⁠-⁠1⁠3 cytokine-induced inflammatory responses, including the release of:

Proinflammatory
cytokines
Proinflammatory
chemokines
IgE
Nitric oxide
The mechanism of dupilumab action in asthma has not been definitively established.

DUPIXENT inhibits signaling of I⁠L⁠-⁠4 and I⁠L⁠-⁠1⁠3, two cytokines that contribute to the inflammation in asthma

  • DUPIXENT is a human monoclonal antibody that specifically binds to the I⁠L⁠-⁠4Rα subunit shared by receptor complexes for I⁠L⁠-⁠4 and I⁠L⁠-⁠1⁠3
  • DUPIXENT inhibits I⁠L⁠-⁠4 signaling via the Type I receptor and both I⁠L⁠-⁠4 and I⁠L⁠-⁠1⁠3 signaling through the Type II receptor

DUPIXENT MyWay®

See how eligible patients can access support for DUPIXENT

LEARN MORE

LEARN MORE ABOUT DUPIXENT

as add-on maintenance therapy
in moderate-to-severe asthma patients

REGISTER FOR UPDATES


Reference: DUPIXENT Prescribing Information. October 2018.